BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · page 7 of 15
The slide outlines the primary endpoint (Clinical Response) and a secondary/supporting metric (piecewise slope) for ALS clinical trials.
Conference presentation · appendix_methodology · present_framework · dense density
Slide locked Sign in to view
Slide schematic 5/5
callout 2/2 paragraph 1/1 source-note 1/1 title 1/1
Components 5
primary primary paragraph source-note headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.